Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers.

ABSTRACT:

Background

Intrahepatic cholangiocarcinoma (ICC) is a challenging primary liver cancer with a poor prognosis, especially in unresectable cases. Traditional palliative irradiation is limited in reducing liver doses. This study aimed to evaluate the efficacy and toxicity of respiratory-gated proton beam therapy without fiducial markers for intrahepatic cholangiocarcinoma.

Methods

Between October 2011 and February 2022, 24 patients (median [range] age, 71 [41-88] years) were evaluated at our institution. Twelve patients were pathologically diagnosed with ICC. All patients underwent respiratory-gated proton beam therapy at a dose of 48-83.6 (relative biological effectiveness) in 20-38 fractions with four-dimensional computed tomography planning. The median follow-up period was 1

SUBMITTER: Okubo A 

PROVIDER: S-EPMC11562633 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature